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CYCLIND dysregulation (an NF-κB 
target gene), correlate or cooperate 
with genetic activation of NF-κB.
By using NF-κB target gene 
expression profiles to identify MM 
patients likely to have TRAF3 dele-
tions among cohorts of patients 
treated with dexamethasone versus 
bortezomib, Keats et al. found that 
only 2/20 patients with TRAF3 inacti-
vation responded to dexamethasone, 
whereas 17/19 patients among the 
TRAF3 inactivation group responded 
to bortezomib. These results sug-
gest that constitutive activation of 
the NF-κB pathway through TRAF3 
inactivation is correlated with dexa-
methosone resistance and bortezo-
mib sensitivity. Although the exact 
molecular basis for the differential 
sensitivity of individual MM patients 
to bortezomib versus dexamethasone 
is not clear, it appears that TRAF3 
status, which can be assessed fairly 
simply by conventional molecular 
techniques, should dictate treatment 
with proteasome inhibitors.
These two studies add to the 
growing body of evidence demon-
strating that mutations in NF-κB 
pathway genes are rather common 
occurrences in a variety of malig-
nancies (Courtois and Gilmore, 
2006). Why certain NF-κB-activat-
ing gene mutations appear to occur 
only in some types of tumors is 
not clear. Nevertheless, the current 
studies take us one step closer to 
understanding the molecular under-
pinnings of MM and toward design-
ing and designating more effective 
therapies for individuals with MM.
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New drugs that neutralize the antiapoptotic members of the Bcl-2 family hold promise for rational 
cancer therapies, both alone and in combination with other agents. An understanding of how 
and why such agents may trigger apoptosis on their own, and how resistance to these drugs 
can occur, depends on the complexity of the Bcl-2 family interactions that control mitochondrial 
outer membrane permeabilization (MOMP). By extracting mitochondria from tumor cells and 
exposing them to peptides corresponding to the regulatory BH3-only proteins, MOMP predicts 
not only which cells will undergo apoptosis in response to Bcl-2 antagonists, but also why other 
cells may be resistant.As any poet or philosopher can tell 
us, it is in the contemplation of death 
that we gain insight into life. Indeed, it 
was in their seminal The Meaning of Life that Monty Python had a dinner 
guest challenge the figure of Death 
to explain how their entire party had 
somehow all died at the same time, to Cancer Cell 1which Death ominously replied, “The 
salmon mousse.” In much the same 
way, if perhaps less ethereally, the 
study of the principles of cell death 2, August 2007 ©2007 Elsevier Inc. 97
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to preserve life, by, among 
other things, providing new 
insights for the treatment 
of cancer. In this issue of 
Cancer Cell, Deng and col-
leagues (2007) probe the 
mechanisms of sensitivity 
and resistance of tumor 
cells to the Bcl-2 antagonist 
ABT-737 and, in so doing, 
offer compelling evidence 
for an emerging view of the 
functions of the Bcl-2 fam-
ily proteins in the control of 
apoptosis. This is a view 
that may, ultimately, give us 
the equivalent of a “salmon 
mousse” for cancer.
Our story concerns the 
intrinsic, or mitochondrial 
pathway of apoptosis, in 
which mitochondrial outer 
membrane permeabiliza-
tion (MOMP) results in 
diffusion of proteins from 
the intermembrane space 
to the cytosol. Holocy-
tochrome c thus gains 
access to APAF-1, leading 
to caspase activation and 
death. Even without caspase acti-
vation, MOMP generally results in 
cell death. The decision, MOMP or 
no MOMP, translating into death or 
survival of the cell, is made by the 
interactions of the Bcl-2 family pro-
teins, both pro- and antiapoptotic. 
Of these, Bax and Bak are the pro-
apoptotic “effectors,” which are likely 
to be directly responsible for the per-
meabilization of the outer membrane. 
These are antagonized by the actions 
of the antiapoptotic Bcl-2 proteins, 
including Bcl-2, Bcl-xL, Mcl-1, and 
Bfl/A1. A third class of Bcl-2 pro-
teins, the BH3-only proteins, appear 
to make the “thumbs up or thumbs 
down” decision by regulating the 
other family members. Recently, sev-
eral drugs that act as BH3 mimetics 
have been identified, including ABT-
737, which antagonizes the functions 
of Bcl-2, Bcl-xL, and Bcl-w and has 
shown potent single-agent proapop-
totic activity in some experimental 
tumors, but not others (Oltersdorf 
et al., 2005). Importantly, ABT-737 is 
generally inactive in triggering apop-
tosis in normal cells, with an interest-
ing exception being platelets.
To understand how this works, 
and to further delineate mechanisms 
of resistance to ABT-737, Deng et 
al. (2007) examined a number of 
ABT-737-sensitive or -resistant dif-
fuse large B cell lymphoma lines 
(DLBCL) by their method of “BH3 
profiling” (Certo et al., 2006). They 
isolated mitochondria from the dif-
ferent lines and exposed them to a 
panel of peptides corresponding to 
the BH3 regions of several BH3-only 
proteins and examined MOMP. In so 
doing, they identified three classes of 
resistance to ABT-737 and provided 
explanations for how they work.
This approach depends on an 
understanding of the functions of 
the different BH3-only proteins (Fig-
ure 1). There is general agreement 
that these proteins act to neutralize 
the antiapoptotic Bcl-2 proteins, and 
they show distinct preferences in this 
function (Certo et al., 2006; Chen et 
al., 2005; Kuwana et al., 
2005), a function termed 
“sensitizer” or “derepres-
sor” activity. The BH3-only 
protein BAD, for example, 
neutralizes Bcl-2, Bcl-xL, 
and Bcl-2, but neither Mcl-
1 nor Bfl/A1, while another 
BH3-only protein, NOXA, 
neutralizes Mcl-1 (and to 
some extent Bfl/A1) but 
none of the others. BIM, 
PUMA, and probably BMF 
effectively bind and neu-
tralize all of the different 
antiapoptotic Bcl-2 pro-
teins. One prevalent view 
is that this neutralization 
of the antiapoptotic Bcl-2 
proteins is not only neces-
sary but also sufficient to 
cause MOMP via Bax and 
Bak (Willis et al., 2007).
Letai et al. (2002) and 
Kuwana et al. (2005) pro-
posed an additional activ-
ity of some BH3-only pro-
teins that is also necessary 
for MOMP: the activation 
of Bax and/or Bak. BH3-
only proteins that have this 
“direct activator” function include 
BIM and BID. However, a recent 
study has shown that Bcl-2-inhibit-
able apoptosis proceeds in BID-BIM 
double knockout cells (Willis et al., 
2007), leading to two possible con-
clusions; either the “direct activator” 
concept is wrong, or other mecha-
nisms exist to activate Bax and Bak. 
I favor the latter and have proposed 
that such alternative mechanisms 
exist (Green, 2006). Cells in which 
direct activators of Bax and/or Bak 
are present are therefore “primed for 
death” such that disruption of the 
antiapoptotic Bcl-2 functions results 
in death (Certo et al., 2006).
It is in this context that Deng et 
al. (2007) characterize the DLBCL 
lines in their study and describe 
three classes of resistance to ABT-
737. In the first (class A), Bax and 
Bak are functional, but no signal is 
present to activate these effectors, 
and therefore no death occurs when 
antiapoptotic Bcl-2 proteins are 
neutralized. Mitochondria from such 
figure 1. BH3 Profiling
Different BH3-only proteins or their corresponding BH3 peptides ef-
fectively neutralize different antiapoptotic Bcl-2 family members, and 
this may or may not lead to MOMP, depending on the status of the pro-
apoptotic effectors Bax and Bak (the pink “salmon mousse”). These 
effectors do not promote death on their own, but do so if exposed 
to direct activator proteins or conditions (the green ptomaine), which 
include the BH3-only protein BIM but also other proteins as well. Ac-
tivated Bax and Bak do not trigger MOMP; however, antiapoptotic 
proteins block MOMP (the hostess preventing the guests from eating), 
unless these inhibitors are effectively neutralized. Such neutralization 
can occur by binding to BH3-only proteins or BH3-mimetic drugs. 
MOMP, when it occurs, leads to cell death (the Grim Reaper). The pat-
tern of MOMP occurrence in response to different BH3-only proteins 
predicts whether or not the drug ABT-737 will cause apoptosis and 
defines three classes of resistance to this drug, A, B, and C.98 Cancer Cell 12, August 2007 ©2007 Elsevier Inc.
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the direct activator BH3 sequences 
from BID or BIM, but not in response 
to the other BH3s. In this setting, 
neutralizing the antiapoptotic pro-
teins with ABT-737 does not induce 
MOMP or death, because Bax or 
Bak is not engaged. In support of 
this idea, Deng et al. (2007) show 
that a cell line that is normally sensi-
tive to apoptosis induction by ABT-
737 is rendered resistant by knock-
ing down one of the direct activator 
BH3-only proteins, BIM.
In their second class of resistance 
(class B), low or absent Bax and 
Bak appear to be responsible, and 
mitochondria from these cells do not 
undergo MOMP in response to any of 
the BH3 peptides. In such cells, neu-
tralization of antiapoptotic proteins 
would not be expected to cause death 
unless some way to induce expression 
of Bax or Bak could be managed.
The third resistance class (class C) 
is one that they (Del Gaizo Moore et 
al., 2007) and others (Konopleva et 
al., 2006) had previously described 
for other types of lymphoma. In these 
cells, direct activators and Bax and/
or Bak are present, and the cells are 
“primed for death,” but the antiapop-
totic Bcl-2 proteins sustaining survival 
are not affected by the drug. In AML 
and CLL, the presence of Mcl-1 corre-
lated with such resistance, and mito-
chondria from such cells underwent 
MOMP in response to NOXA BH3. In 
the current study, one such resistant 
line was found to overexpress Bfl/A1.
Is this emerging, complex view 
important? The simpler view, dis-
cussed above, that neutralization 
of all available antiapoptotic Bcl-2 
family proteins is both necessary 
and sufficient for apoptosis does 
not account for the data presented 
by Deng et al. (2007). For example, 
while both BIM and PUMA interact 
with all of the antiapoptotic Bcl-
2 proteins with equivalent affinity 
(e.g., Chen et al., 2005), BIM but 
not PUMA was observed to induce 
MOMP in mitochondria from class 
A cells. One recent report (Kim et 
al., 2006) suggested that PUMA, 
like BIM and BID, is a direct activa-
tor BH3; however, this appears to be incompatible with the above results 
as well, at least under these experi-
mental conditions.
Perhaps more importantly, the 
emerging view laid out by Deng et al. 
(2007) is compatible with the idea that 
a therapeutic window may exist for 
BH3-mimetic drugs, such as ABT-737, 
to preferentially kill tumors rather than 
normal tissues. In any simpler view, no 
such window should logically exist, 
since tumors should be expected to 
have equal or higher levels of antiapop-
totic proteins as compared to normal 
tissues, and thus be more resistant 
than normal cells to their neutraliza-
tion. However if tumors are preferen-
tially “primed for death” by direct acti-
vators of Bax and/or Bak, then they 
may have increased sensitivity to such 
neutralizers, unless they belong to one 
of the classes of resistance described 
by Deng et al. (2007). Such priming 
may occur, in part, because onco-
genes that drive proliferation can also 
engage direct activators of Bax and 
Bak. For example, c-Myc drives the 
function of BIM (Egle et al., 2004).
In keeping with these notions, 
one recent study explores another 
drug, TW-37, which neutralizes Bcl-
2 and Bcl-xL with affinities similar to 
those of ABT-737, but also effectively 
blocks Mcl-1 (with similar affinity to 
the other antiapoptotic proteins) 
(Verhaegen et al., 2006). A thera-
peutic window was found for mela-
noma versus primary cells in mice, 
a finding that is difficult to reconcile 
with simple “neutralization models” 
of Bcl-2 family function. However, 
if melanoma, like the lymphomas 
studied by Letai and colleagues, are 
“primed for death” by the engage-
ment of direct activators of Bax 
and Bak, then the specificity of this 
drug for transformed cells can make 
sense. We shall see if the patterns 
of resistance defined by Deng et al. 
(2007) apply similarly to this agent. 
Ultimately, the functional mecha-
nisms controlling the Bcl-2 family 
and MOMP may turn out to be very 
much a matter of life and death.
Fully effective tumor therapy 
requires that, like the guests at Monty 
Python’s ill-fated dinner party, every 
targeted cell dies. Combinations of Cancer Celltherapies to engage the mechanisms 
of apoptosis, for example, by con-
ventional radiation or chcmothera-
pies, while inhibiting antiapoptotic 
mechanisms using BH3 mimetics, 
hold promise for new avenues of can-
cer therapy. But it is easy to kill tumor 
cells—the trick is leaving the healthy 
tissues intact. The BH3 profiling 
approach that Letai and colleagues 
have introduced represents a step 
toward teasing out such conditions.
RefeRences
Certo, M., Del Gaizo Moore, V., Nishino, M., 
Wei, G., Korsmeyer, S., Armstrong, S.A., and 
Letai, A. (2006). Cancer Cell 9, 351–365.
Chen, L., Willis, S.N., Wei, A., Smith, B.J., 
Fletcher, J.I., Hinds, M.G., Colman, P.M., Day, 
C.L., Adams, J.M., and Huang, D.C. (2005). 
Mol. Cell 17, 393–403.
Del Gaizo Moore, V., Brown, J.R., Certo, M., 
Love, T.M., Novina, C.D., and Letai, A. (2007). 
J. Clin. Invest. 117, 112–121.
Deng, J., Carlson, N., Takeyama, K., Dal Cin, 
P., Shipp, M., and Letai, A. (2007). Cancer Cell, 
this issue.
Egle, A., Harris, A.W., Bouillet, P., and Cory, 
S. (2004). Proc. Natl. Acad. Sci. USA 101, 
6164–6169.
Green, D.R. (2006). Cancer Cell 9, 328–330.
Kim, H., Rafiuddin-Shah, M., Tu, H.C., Jeffers, 
J.R., Zambetti, G.P., Hsieh, J.J., and Cheng, 
E.H. (2006). Nat. Cell Biol. 8, 1348–1358.
Konopleva, M., Contractor, R., Tsao, T., Samu-
dio, I., Ruvolo, P.P., Kitada, S., Deng, X., Zhai, 
D., Shi, Y.X., Sneed, T., et al. (2006). Cancer 
Cell 10, 375–388.
Kuwana, T., Bouchier-Hayes, L., Chipuk, 
J.E., Bonzon, C., Sullivan, B.A., Green, D.R., 
and Newmeyer, D.D. (2005). Mol. Cell 17, 
525–535.
Letai, A., Bassik, M.C., Walensky, L.D., Sor-
cinelli, M.D., Weiler, S., and Korsmeyer, S.J. 
(2002). Cancer Cell 2, 183–192.
Oltersdorf, T., Elmore, S.W., Shoemaker, 
A.R., Armstrong, R.C., Augeri, D.J., Belli, 
B.A., Bruncko, M., Deckwerth, T.L., Dinges, 
J., Hajduk, P.J., et al. (2005). Nature 435, 
677–681.
Verhaegen, M., Bauer, J.A., Martin de la Vega, 
C., Wang, G., Wolter, K.G., Brenner, J.C., 
Nikolovska-Coleska, Z., Bengtson, A., Nair, 
R., Elder, J.T., et al. (2006). Cancer Res. 66, 
11348–11359.
Willis, S.N., Fletcher, J.I., Kaufmann, T., van 
Delft, M.F., Chen, L., Czabotar, P.E., Ierino, H., 
Lee, E.F., Fairlie, W.D., Bouillet, P., et al. (2007). 
Science 315, 856–859. 12, August 2007 ©2007 Elsevier Inc. 99
